Telmisartan Dosing for Hypertension
Start telmisartan at 40 mg once daily for hypertension, with a dose range of 20-80 mg once daily; no dose adjustment is needed for elderly patients or those with moderate renal impairment, but use lower starting doses (20 mg) in hepatic impairment, and telmisartan is absolutely contraindicated in pregnancy. 1
Standard Hypertension Dosing
The FDA-approved starting dose is 40 mg once daily, with blood pressure response being dose-related across the 20-80 mg range 1. Most antihypertensive effect appears within 2 weeks, with maximal reduction typically achieved after 4 weeks 1. The medication can be taken with or without food, though food reduces bioavailability by approximately 6% at 40 mg and 20% at 160 mg 1.
For cardiovascular risk reduction specifically, the recommended dose is 80 mg once daily 1. This is the only dose proven effective for reducing cardiovascular morbidity and mortality, and blood pressure should be monitored when initiating therapy at this indication 1.
Special Population Adjustments
Hepatic Impairment
Use caution and consider starting at 20 mg in patients with hepatic insufficiency 2. Plasma concentrations increase substantially in hepatic impairment, with absolute bioavailability approaching 100% and total clearance significantly reduced 1, 2. The pharmacokinetic study demonstrated that maximum plasma concentration and AUC increased 6.4-fold and 2.7-fold respectively at the 20 mg dose in hepatically impaired patients 2. Despite increased exposure, telmisartan was well tolerated even at higher doses, but the elevated bioavailability suggests lower doses should be considered 2.
Renal Impairment
No dosage adjustment is necessary for patients with decreased renal function, including those on hemodialysis 1. Telmisartan is eliminated >97% unchanged in feces via biliary excretion, with only minute amounts (0.49-0.91%) found in urine 1. Clinical studies in patients with mild/moderate chronic kidney disease (creatinine clearance 30-74 mL/min/1.73 m²), severe CKD (CrCl <30 mL/min/1.73 m²), and hemodialysis patients demonstrated effective blood pressure control with telmisartan 40-80 mg once daily 3.
Important caveat: Patients on dialysis may develop orthostatic hypotension, so blood pressure should be closely monitored 1.
Elderly Patients
No initial dosage adjustment is necessary for elderly patients 1. The pharmacokinetics of telmisartan do not differ between elderly and those younger than 65 years 1. A large comparative trial in 278 patients aged ≥65 years demonstrated that telmisartan 20-80 mg was as effective as enalapril 5-20 mg, with 63% of patients achieving diastolic BP <90 mmHg 4.
Gender Considerations
While plasma concentrations are 2-3 times higher in females than males, no dosage adjustment is necessary as clinical trials showed no significant increases in blood pressure response or orthostatic hypotension in women 1.
Absolute Contraindication in Pregnancy
Telmisartan and all RAS blockers are absolutely contraindicated during pregnancy 5. The 2024 ESC guidelines explicitly state that RAS blockers are not recommended during pregnancy 5. The 2025 AHA/ACC guidelines recommend labetalol and extended-release nifedipine as preferred first-line agents for hypertension in pregnancy 6. Dihydropyridine CCBs (preferably extended-release nifedipine), labetalol, and methyldopa are the recommended first-line medications 5.
Titration Strategy
If blood pressure remains uncontrolled after 2-4 weeks on 40 mg, titrate to 80 mg once daily 1. The dose-response relationship shows greater than proportional increases in plasma concentrations with increasing doses due to nonlinear pharmacokinetics 1. Telmisartan may be combined with other antihypertensive agents, particularly hydrochlorothiazide, which provides additive blood pressure lowering 1.
Key Pharmacokinetic Considerations
- Half-life: Approximately 24 hours, supporting once-daily dosing 1
- Protein binding: >99.5%, mainly to albumin 1
- Metabolism: Not metabolized by cytochrome P450 enzymes; forms inactive acyl glucuronide 1
- Accumulation: Accumulation index of 1.5-2.0 with once-daily dosing 1
- Peak effect: Trough concentrations are 10-25% of peak, providing sustained 24-hour coverage 1